Tyr3-Octreotate (acetate)

Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) [1].

Product Specifications

UNSPSC

12352209

Target

Radionuclide-Drug Conjugates (RDCs)

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.76

Smiles

O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45.CC(O)=O.CC(O)=O

Molecular Formula

C53H72N10O16S2

Molecular Weight

1169.33

References & Citations

[1]Capello A, et al., Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm. 2003 Oct;18 (5) :761-8.